Abstract:BACKGROUND:Aberrant expression of the RON receptor tyrosine kinase is a pathogenic feature and a validated drug target in various types of cancers. Currently, therapeutic antibodies targeting RON for cancer therapy are under intensive evaluation. Here we report the development and validation of a novel humanized anti-RON antibody-drug conjugate for cancer therapy.METHODS:Antibody humanization was achieved by grafting sequences of complementarity-determining regions from mouse monoclonal antibody Zt/g4 into human IgG1/κ acceptor frameworks. The selected humanized Zt/g4 subclone H1L3 was conjugated with monomethyl auristatin E using a dipeptide linker to form H-Zt/g4-MMAE. Pharmacokinetic analysis of H-Zt/g4-MMAE was determined using hydrophobic interaction chromatography and a MMAE ADC ELISA kit. Biochemical and biological assays were used for measuring RON expression, internalization, cell viability and death. Therapeutic efficacies of H-Zt/g4-MMAE were validated in vivo using three pancreatic cancer xenograft models. Toxicological activities of H-Zt/g4-MMAE were determined in mouse and cynomolgus monkey.RESULTS:H-Zt/g4-MMAE had a drug to antibody ratio of 3.77:1 and was highly stable in human plasma with a dissociation rate less than 5% within a 20 day period. H-Zt/g4-MMAE displayed a favorable pharmacokinetic profile in both mouse and cynomolgus monkey. In vitro, H-Zt/g4-MMAE induced RON internalization, which results in killing of pancreatic cancer cells with IC50 values at 10-20 nM. In vivo, H-Zt/g4-MMAE inhibited pancreatic cancer xenograft growth with tumoristatic concentrations at 1~3 mg/kg bodyweight. Significantly, H-Zt/g4-MMAE eradicated tumors across multiple xenograft models regardless their chemoresistant and metastatic statuses. Moreover, H-Zt/g4-MMAE inhibited and eradicated xenografts mediated by pancreatic cancer stem-like cells and by primary cells from patient-derived tumors. Toxicologically, H-Zt/g4-MMAE is well tolerated in mice up to 60 mg/kg. In cynomolgus monkey, H-Zt/g4-MMAE up to 30 mg/kg had a manageable and reversible toxicity profile.CONCLUSIONS:H-Zt/g4-MMAE is superior in eradication of pancreatic cancer xenografts with favorable pharmacokinetic profiles and manageable toxicological activities. These findings warrant the transition of H-Zt/g4-MMAE into clinical trials in the future.

Construction and expression of humanized anti-EGFR antibody

Successful construction and massive expression of a novel Anti-CD19 human-mouse chimeric antibody Hm2E8b.

[Construction of Eukaryotic Vector and Expression of Chimeric Antibody Against Rh-Bfgf].

Construction and Expression of a Human/mouse Chimeric CD19 Monoclonal Antibody: Successful Modification of a Murine IgM to a Chimeric IgG.

Construction and Expression of Anti-Human CD3 Chimeric Antibody Gene and Preliminary Study of Expressed Product

Construction of anti-VEGFR-2 IgG1 like human antibody and its expression in CHO-k cells

Construction and Expression of a Chimeric Murine-Human Antibody Against VEGF165

Construction and Expression of Single-Chain Antibody Derived from a New Clone of Monoclonal Antibody Against Human CD14 in CHO Cells

Construction, Expression, and Characterization of a Novel Human-Mouse Chimeric Antibody, Hm3A4: A Potential Therapeutic Agent for B and Myeloid Lineage Leukemias.

Analysis of the in vitro function and internalization ability of a humanized EGFR antibody AE01 expressed by Chinese hamster ovary cells

Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

[Construction and expression of chimeric anti-human CD20 monoclonal antibody].

[Gene's Construction, Expression and Activity Analysis of Humanized Single-Domain Antibody Against Human Lung Cancer].

Generation and Characterization of a Novel Human IgG1 Antibody Against Vascular Endothelial Growth Factor Receptor 2

Construction of a Human Monoclonal Antibody Against Bfgf for Suppression of NSCLC.

The Construction of Anti-EGFR Single Chain Variable Fragment Fused with Gelonin Toxin Prokaryotic Expressing Plasmid and the Study of Its Anti-tumor Effects

[Construction and Expression of Human-Mouse Chimeric Antibody Against Human CD40].

Preparation and Biological Activity of Anti-Human C-Mesenchymal Epithelial Transition Factor (C-Met) Monovalent Antibody

Generation of Fully Human Anti-Gpc3 Antibodies with High-Affinity Recognition of GPC3 Positive Tumors

Preparation and enhanced eukaryotic expression of anti-human CD40 antibodies

Expression and Characterization of Recombinant Humanized Anti-Her2 Single-Chain Antibody in Pichia Pastoris for Targeted Cancer Therapy